Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D63, 4 or *5 allele.

European journal of clinical pharmacology - 1 May 2008

Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H

Abstract excerpt

OBJECTIVE: Increased systemic exposure of the antidepressant venlafaxine and increased risk of side effects has previously been observed in patients with defective CYP2D6 function [poor metabolisers (PMs)]. The aim of this study was to evaluate venlafaxine pharmacokinetics in carriers of one functional and one defective CYP2D6 allele [heterozygous extensive metabolisers (HEMs)]. METHODS: Data was collected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alleles

Share to Antidepressive Agents, Second-Generation

Share to Cyclohexanols

Share to Cytochrome P-450 CYP2D6

Share to Heterozygote

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 18214456
DOI: 10.1007/s00228-007-0453-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.PMID 18214456Read ↗

The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.Semantic proximity Read ↗

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.Semantic proximity Read ↗

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.Semantic proximity Read ↗

An observational study of Venlafaxine and CYP2D6 in clinical practice.Semantic proximity Read ↗

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.Semantic proximity Read ↗

Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.Semantic proximity Read ↗

Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.Semantic proximity Read ↗

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.Semantic proximity Read ↗

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.Semantic proximity Read ↗

CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.Semantic proximity Read ↗

Cytochrome P450 2D6 genotype variation and venlafaxine dosage.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.